The federal government has placed its first order for an antibiotic reserved for infections that other drugs can no longer treat. Shionogi announced on August 28 that the Biomedical Advanced Research and Development Authority exercised a $36.9 million procurement option for Fetroja, known generically as cefiderocol.
It is the first option exercised under a contract awarded to the company's New Jersey-based U.S. subsidiary in April, with initial funding of $119 million and multiyear options that could total $482 million.
